Literature DB >> 17556621

The Anopheles gambiae vitellogenin gene (VGT2) promoter directs persistent accumulation of a reporter gene product in transgenic Anopheles stephensi following multiple bloodmeals.

Xiao-Guang Chen1, Osvaldo Marinotti, Lucia Whitman, Nijole Jasinskiene, Anthony A James, Patricia Romans.   

Abstract

Mosquitoes made resistant to pathogens through genetic engineering are proposed as a basis for developing a strategy to control disease transmission. Transgenic approaches that introduce exogenous antipathogen effector genes into mosquito genomes require cis-acting regulatory DNA to control tissue-, stage-, and sex-specific transgene expression. We show that control sequences derived from a vitellogenin-encoding gene of Anopheles gambiae, a major vector in sub-Saharan Africa, can direct expression of an exogenous gene in a tissue-, stage-, and sex-specific manner in Anopheles stephensi, a vector of urban malaria in southern Asia. Specific reporter gene expression was observed in fat-body tissues of transgenic blood-fed females, but not in transgenic males or non-blood-fed transgenic females. Multiple bloodmeals resulted in the continuous presence of reporter gene transcripts for at least 12 days. The persistent expression makes the heterologous promoter a good candidate for controlling transcription of engineered antipathogen effector genes in this important malaria vector.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556621

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  Vitellogenin gene expression in autogenous Culex tarsalis.

Authors:  K N Provost-Javier; S Chen; J L Rasgon
Journal:  Insect Mol Biol       Date:  2010-04-27       Impact factor: 3.585

Review 2.  Gene expression studies in mosquitoes.

Authors:  Xiao-Guang Chen; Geetika Mathur; Anthony A James
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

Review 3.  Malaria vector control: from past to future.

Authors:  Kamaraju Raghavendra; Tapan K Barik; B P Niranjan Reddy; Poonam Sharma; Aditya P Dash
Journal:  Parasitol Res       Date:  2011-01-13       Impact factor: 2.289

Review 4.  Molecular genetic manipulation of vector mosquitoes.

Authors:  Olle Terenius; Osvaldo Marinotti; Douglas Sieglaff; Anthony A James
Journal:  Cell Host Microbe       Date:  2008-11-13       Impact factor: 21.023

5.  Comparative genomics allows the discovery of cis-regulatory elements in mosquitoes.

Authors:  Douglas H Sieglaff; W Augustine Dunn; Xiaohui S Xie; Karyn Megy; Osvaldo Marinotti; Anthony A James
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

6.  Duplication, concerted evolution and purifying selection drive the evolution of mosquito vitellogenin genes.

Authors:  Song Chen; Jennifer S Armistead; Katie N Provost-Javier; Joyce M Sakamoto; Jason L Rasgon
Journal:  BMC Evol Biol       Date:  2010-05-13       Impact factor: 3.260

Review 7.  Transgenesis and paratransgenesis to control insect-borne diseases: current status and future challenges.

Authors:  Iliano V Coutinho-Abreu; Kun Yan Zhu; Marcelo Ramalho-Ortigao
Journal:  Parasitol Int       Date:  2009-10-09       Impact factor: 2.230

8.  Anopheles gambiae blood feeding initiates an anticipatory defense response to Plasmodium berghei.

Authors:  Leanna M Upton; Michael Povelones; George K Christophides
Journal:  J Innate Immun       Date:  2014-09-19       Impact factor: 7.349

9.  Engineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi.

Authors:  Alison T Isaacs; Fengwu Li; Nijole Jasinskiene; Xiaoguang Chen; Xavier Nirmala; Osvaldo Marinotti; Joseph M Vinetz; Anthony A James
Journal:  PLoS Pathog       Date:  2011-04-21       Impact factor: 6.823

10.  Analysis of two novel midgut-specific promoters driving transgene expression in Anopheles stephensi mosquitoes.

Authors:  Tony Nolan; Elisa Petris; Hans-Michael Müller; Ann Cronin; Flaminia Catteruccia; Andrea Crisanti
Journal:  PLoS One       Date:  2011-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.